RESÚMENES SEPTIEMBRE 2008

.

Other Neuropsychiatric Disorders & General Information

 (Haga un click en la información del journal para acceder al resúmen)

5 – doble-ciego o metanálisis; 4 – subanálisis o simple ciego; 3 – revisión, abierto, básico; 2 – casos; 1 – opinión

GRATIS = Texto gratuito en algunos países de la región iberoamericana (algunos artículos requieren ir a la tabla de contenidos del número actual de la revista)

 

GRATIS 3 - Beneficial effect of pramipexole for motor function and depression in Parkinson’s disease

Osamu Kano, Ken Ikeda, Tetsuhito Kiyozuka, Konosuke Iwamoto, Hirono Ito, Yuji Kawase, Ryuta Sato, Toshiki Fujioka, Yo Araki, Shigeji Baba, Yasuo Iwasaki

Neuropsychiatric Disease and Treatment. Issue 4. September 2008

 

3! - Treatment of Severe Agitation with Olanzapine in 166 Patients with Schizophrenia, Schizoaffective, or Bipolar I Disorder

M. Lambert, C. G. Huber, D. Naber, A. Schacht,T. T. Wagner, H.-P. Hundemer, A. Karow, B. G. Schimmelmann

Pharmacopsychiatry 2008; 41: 182-189

3 - Preliminary Evidence of Improvement of Depressive Symptoms but not Impulsivity in Cluster B Personality Disorder Patients Treated with Quetiapine: an Open Label Trial

S. Roepke, A. Merkl, A. Dams, A. Ziegenhorn,I. G. Anghelescu, I. Heuser, C. H. Lammers

Pharmacopsychiatry 2008; 41: 176-181

3 - Approved and Investigational Uses of Modafinil: An Evidence-Based Review

Kumar, Raminder

Drugs, Volume 68, Number 13, 2008 , pp. 1803-1839

 

3! - Effect of Physical Activity on Cognitive Function in Older Adults at Risk for Alzheimer Disease. A Randomized Trial

Nicola T. Lautenschlager, Kay L. Cox, Leon Flicker, Jonathan K. Foster, Frank M. van Bockxmeer, Jianguo Xiao, Kathryn R. Greenop, Osvaldo P. Almeida

JAMA. 2008;300(9):1027-1037

 

3! - Ethnicity as a variable in mental health research: A systematic review of articles published 1990-2004

S Mollersen; A. Holte

Nordic Journal of Psychiatry, Volume 62, Issue 4 2008, pages 322 - 328

 

3! - A systematic review on the effectiveness of treatment with antidepressants in fibromyalgia syndrome

Nurcan Üçeyler, Winfried Häuser, Claudia Sommer

Arthritis Care & Research. Volume 59 Issue 9, Pages 1279 - 1298

 

3! - Inappropriate benzodiazepine use in older adults and the risk of fracture

Cornelis S. van der Hooft, Mariëtte W. C. J. Schoofs, Gijsbertus Ziere, Albert Hofman, Huibert A. P. Pols, Miriam C. J. M. Sturkenboom & Bruno H. Ch. Stricke

British Journal of Clinical Pharmacology. Volume 66 Issue 2, Pages 276 - 282

 

3 - The Effects of Age and Sex on Electroconvulsive Therapy Using Remifentanil as the Sole Anesthetic Agent

Hossain, Akm; Sullivan, Pamela

Journal of ECT. 24(3):232-235, September 2008

3 - Effects of General Anesthetic Agents in Adults Receiving Electroconvulsive Therapy: A Systematic Review

Hooten, W. Michael; Rasmussen, Keith G. Jr

Journal of ECT. 24(3):208-223, September 2008

3 - Effects of the Addition of Remifentanil to Propofol Anesthesia on Seizure Length and Postictal Suppression Index in Electroconvulsive Therapy

Porter, Richard; Booth, David; Gray, Hamish; Frampton, Chris

Journal of ECT. 24(3):203-207, September 2008

3 - Efficacy of topiramate in bulimia nervosa and binge-eating disorder: a systematic review

Beatriz Arbaizar, Inés Gómez-Acebo B and Javier Llorca

General Hospital Psychiatry. Volume 30, Issue 5, September-October 2008, Pages 471-475

 

3 - Using risperidone for Alzheimer's dementia-associated psychosis

Karleen M McNeal, Renee P Meyer, Karen Lukacs, Anna Senseney & Jacob Mintzer

Expert Opinion on Pharmacotherapy. October 2008, Vol. 9, No. 14, Pages 2537-2543

 

3! - Safety and tolerability of duloxetine treatment of diabetic peripheral neuropathic pain between patients with and without cardiovascular conditions

Joachim F. Wernicke, Apurva Prakash, Daniel K. Kajdasz and John Houston

Journal of Diabetes and its Complications. Article in Press, September 2008

 

5 - Triple-Bead Mixed Amphetamine Salts (SPD465), a Novel, Enhanced Extended-Release Amphetamine Formulation for the Treatment of Adults With ADHD: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study

Thomas J. Spencer, Lenard A. Adler, Richard H. Weisler, and Sharon H. Youcha

J Clin Psychiatry 2008;69:1437-1448

 

3! - Worldwide variation in the doubling time of Alzheimer's disease incidence rates

Kathryn Ziegler-Graham, Ron Brookmeyer, Elizabeth Johnson and H. Michael Arrighi

Alzheimer's and Dementia. Volume 4, Issue 5, September 2008, Pages 316-323

 

3! - Onset of terminal decline in cognitive abilities in individuals without dementia

V. Thorvaldsson, S. M. Hofer, S. Berg, I. Skoog, S. Sacuiu, and B. Johansson

NEUROLOGY 2008;71:882-887

5 - Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder

Lenard A. Adler, David W. Goodman, Scott H. Kollins, Richard H. Weisler, Suma Krishnan, Yuxin Zhang, and Joseph Biederman, on behalf of the 303 Study Group

J Clin Psychiatry 2008;69:1364-1373

 

3 - Is rimonabant efficacious and safe in the treatment of obesity?

Sheila A Doggrell

Expert Opinion on Pharmacotherapy. October 2008, Vol. 9, No. 15, Pages 2727-2731

 

3 - FDG-PET Study in Pathological Gamblers. Lithium Increases Orbitofrontal, Dorsolateral and Cingulate Metabolism
Eric Hollander, Monte S. Buchsbaum, M. Mehmet Haznedar, Jessica Berenguer, Heather A. Berlin, William Chaplin, Chelain R. Goodman, Elizabeth M. LiCalzi, Randall Newmark, Stefano Pallanti
Neuropsychobiology 2008;58:37-47

 

3! - Evidenced-based pharmacologic treatment of borderline personality disorder: A shift from SSRIs to anticonvulsants and atypical antipsychotics?

P. Francis Abraham and Joseph R. Calabrese

Journal of Affective Disorders. Volume 111, Issue 1, November 2008, Pages 21-30

 

3! - New episodes and new onsets of major depression in borderline and other personality disorders

John G. Gunderson, Robert L. Stout, Charles A. Sanislow, M. Tracie Shea, Thomas H. McGlashan, Mary C. Zanarini, Maria T. Daversa, Carlos M. Grilo, Shirley Yen and Andrew E. Skodol

Journal of Affective Disorders. Volume 111, Issue 1, November 2008, Pages 40-45

 

3! - Childhood cognitive ability and risk of late-onset Alzheimer and vascular dementia

Brian McGurn, Ian J. Deary, and John M. Starr

NEUROLOGY 2008;71:1051-1056

3 - Effects of 5-HT6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat

B Marcos, T T Chuang, F J Gil-Bea and M J Ramirez

British Journal of Pharmacology (2008) 155, 434–440

 

GRATIS 3 - Safety and Efficacy of Rivastigmine in Patients With Alzheimer's Disease Not Responding Adequately to Donepezil: An Open-Label Study

Gary S. Figiel, Carl H. Sadowsky, John Strigas, M.S., Barbara Koumaras, Xiangyi Meng, and Ibrahim Gunay

Prim Care Companion J Clin Psychiatry. 2008; 10(4): 291–298

 

GRATIS 3! - Diagnosing and treating attention-deficit/hyperactivity disorder in adults

V. FARAONE STEPHEN and M. ANTSHEL KEVIN

World Psychiatry. 2008 October; 7(3): 131–136

 

GRATIS 3! - Neurosurgical strategies for Gilles de la Tourette’s syndrome

Karim Mukhida, Matthew Bishop, Murray Hong, Ivar Mendez

Neuropsychiatric Disease and Treatment. ON-LINE EARLY. September 2008

 

3 - New treatment options in the management of fibromyalgia: role of pregabalin

Grazyna Zareba

Neuropsychiatric Disease and Treatment. ON-LINE EARLY. September 2008

 

GRATIS 3 - The efficacy of mirtazapine in agitated patients with Alzheimer’s disease: A 12-week open-label pilot study

Sibel Cakir, Isin Baral Kulaksizoglu

Neuropsychiatric Disease and Treatment. ON-LINE EARLY. September 2008

.

Regresar a RESÚMENES SEPTIEMBRE 2008

.

© 1999-2008 Jorge M Tamayo, MD, BMSS

Creada en Enero 1999

Declaración: El contenido de esta página web está basado en las revisiones de la literatura realizadas por el autor y las colaboraciones enviadas por los lectores. Este sitio de Internet está dirijido únicamente a profesionales de la salud en Iberoamérica. Si usted es residente de Estados Unidos de América o Europa, debe tener en cuenta que los contenidos no han sido escogidos con base en información aprobada por la FDA o la EMEA.